Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label].
Marketing Status approved; investigational
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 63304-191; 0054-0401; 0054-0603; 14501-0068; 70436-013; 70771-1311; 68382-469; 0054-0400; 70436-036; 70771-1312; 0591-3660; 71335-1815; 68382-105; 46708-152; 70518-3195; 69766-025; 60687-607; 63304-192; 70771-1661; 68382-741; 72888-144; 46708-153; 53002-1801; 71335-1753; 71335-1975; 72888-143; 63629-7524; 70436-012; 0591-3659; 71335-1700; 0591-4060; 50090-4806
UNII NG99554ANW
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.0020.002050%Not Available
Abnormal behaviour19.01.01.0010.001836%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Feeling of body temperature change08.01.09.0120.000178%Not Available
Erectile dysfunction21.03.01.007; 19.08.04.0010.000998%
Inner ear disorder04.04.02.002--Not Available
Parkinson's disease17.01.05.0100.000267%Not Available
Immunodeficiency10.03.02.0020.000178%Not Available
Adverse drug reaction08.06.01.009--Not Available
Autoimmune disorder10.04.04.0030.000267%
Drug intolerance08.06.01.0130.006294%Not Available
Psychotic disorder19.03.01.0020.001195%
Sinus disorder22.04.06.0020.000481%
Poor quality sleep19.02.05.005; 17.15.04.0020.000606%Not Available
Head titubation17.01.06.0060.000606%Not Available
Suicidal behaviour19.12.01.0060.000535%Not Available
Abdominal wall haemorrhage12.01.17.002; 24.07.02.036; 07.16.05.002--Not Available
Skin mass23.07.04.0140.000178%Not Available
Brain injury19.07.03.007; 17.11.01.0030.000178%Not Available
Fasting26.01.02.001--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.001212%
Reversible cerebral vasoconstriction syndrome24.04.06.026; 18.06.01.004; 17.08.02.0140.000267%Not Available
Depersonalisation/derealisation disorder19.14.01.0040.000267%Not Available
Coeliac disease14.02.01.007; 10.04.04.012; 07.17.01.0080.000446%Not Available
Impulsive behaviour19.18.01.0010.000357%Not Available
Persecutory delusion19.10.01.0070.000178%Not Available
Social fear19.06.03.011--Not Available
Negative thoughts19.15.02.012--Not Available
The 10th Page    First    Pre   10 11    Next   Last    Total 11 Pages